TP53 mutations in older adults with acute myeloid leukemia

International Journal of Hematology
Masamitsu YanadaNobuhiko Emi

Abstract

The net benefits of induction therapy for older adults with acute myeloid leukemia (AML) remain controversial. Because AML in older adults is a heterogeneous disease, it is important to identify those who are unlikely to benefit from induction therapy based on information available at the initial assessment. We used next-generation sequencing to analyze TP53 mutation status in AML patients aged 60 years or older, and evaluated its effects on outcomes. TP53 mutations were detected in 12 of 77 patients (16 %), and there was a significant association between TP53 mutations and monosomal karyotype. Patients with TP53 mutations had significantly worse survival than those without (P = 0.009), and multivariate analysis identified TP53 mutation status as the most significant prognostic factor for survival. Neverthelsess, TP53-mutated patients had a 42 % chance of complete remission and a median survival of 8.0 months, which compares favorably with those who did not undergo induction therapy, even in the short term. These results suggest that screening for TP53 mutations at diagnosis is useful for identifying older adults with AML who are least likely to respond to chemotherapy, although the presence of this mutation alone does not seem...Continue Reading

References

Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Aug 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
Jan 24, 2009·Nature Reviews. Cancer·Catherine WhibleyMonica Hollstein
Jun 24, 2011·Leukemia Research·Harshabad SinghEyal C Attar
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roland B WalterElihu H Estey
Jul 10, 2012·Haematologica·Betul Oran, Daniel J Weisdorf
Jul 14, 2012·International Journal of Hematology·Masamitsu Yanada, Tomoki Naoe
Mar 22, 2014·Cancer Cell·Patricia A J Muller, Karen H Vousden
Jul 6, 2014·International Journal of Hematology·Soo-Jeong KimUNKNOWN Korean Society of Hematology AML/MDS Working Party
Mar 31, 2015·International Journal of Hematology·Masamitsu YanadaNobuhiko Emi

❮ Previous
Next ❯

Citations

Sep 21, 2018·Leukemia & Lymphoma·Christine M McMahon, Alexander E Perl
Jan 11, 2020·Current Opinion in Hematology·Hannah Asghari, Chetasi Talati
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Andrew KuykendallJohn S Welch
Nov 24, 2018·Best Practice & Research. Clinical Haematology·John S Welch
Apr 13, 2018·Science Translational Medicine·Luis A CarvajalUlrich Steidl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.